NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
External Expert Profile
Emma Hawe
Latest Publications
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
The Lower Drug Costs Now Act and Pharmaceutical Innovation
How is Quality of Life Measured for Health Technology Assessments?
Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold
